The impact of antihypertensives on kidney disease

F1000Research
Diego F MarquezLuis M Ruilope

Abstract

Arterial hypertension and chronic kidney disease (CKD) are intimately related. The control of blood pressure (BP) levels is strongly recommended in patients with CKD in order to protect the kidney against the accompanying elevation in global cardiovascular (CV) risk. Actually, the goal BP in patients with CKD involves attaining values <140/90 mmHg except if albuminuria is present. In this case, it is often recommended to attain values <130/80 mmHg, although some guidelines still recommend <140/90 mmHg. Strict BP control to values of systolic BP around 120 mmHg was recently shown to be safe in CKD according to data from the SPRINT trial, albeit more data confirming this benefit are required. Usually, combination therapy initiated with an angiotensin receptor blocker (ARB) or angiotensin-converting enzyme inhibitor (ACEi) and commonly followed by the addition of a calcium channel blocker and a diuretic is needed. Further studies are required as well as new drugs in particular after the positive data obtained from new oral anti-diabetic drugs.

References

Nov 21, 2002·JAMA : the Journal of the American Medical Association·Jackson T WrightUNKNOWN African American Study of Kidney Disease and Hypertension Study Group
Aug 26, 2003·Journal of the American Society of Nephrology : JASN·Thomas H Hostetter, Hassan N Ibrahim
Nov 2, 2004·The New England Journal of Medicine·Piero RuggenentiUNKNOWN Bergamo Nephrologic Diabetes Complications Trial (BENEDICT) Investigators
Jul 19, 2006·Annals of Internal Medicine·Kevin DouglasJeffrey L Jackson
Aug 3, 2006·Kidney International·P A Sarafidis, G L Bakris
Jan 25, 2008·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Andrew S BombackPhilip J Klemmer
Apr 2, 2008·The New England Journal of Medicine·UNKNOWN ONTARGET InvestigatorsCraig Anderson
Jul 9, 2009·Journal of Hypertension·Luis M RuilopeEberhard Ritz
Mar 17, 2010·The New England Journal of Medicine·William C CushmanFaramarz Ismail-Beigi
Sep 8, 2010·The New England Journal of Medicine·Lawrence J AppelUNKNOWN AASK Collaborative Research Group
Mar 11, 2011·The New England Journal of Medicine·Hermann HallerUNKNOWN ROADMAP Trial Investigators
Aug 16, 2011·Lancet·Andrew S Levey, Josef Coresh
Feb 18, 2012·JAMA : the Journal of the American Medical Association·Stefan D Anker, Stephan von Haehling
Mar 10, 2012·Journal of the American Society of Nephrology : JASN·Bo HuUNKNOWN African-American Study of Kidney Disease and Hypertension Group
Oct 23, 2012·Journal of the American College of Cardiology·Min JunVlado Perkovic
Nov 6, 2012·The New England Journal of Medicine·Hans-Henrik ParvingUNKNOWN ALTITUDE Investigators
Apr 25, 2013·Journal of Renal Nutrition : the Official Journal of the Council on Renal Nutrition of the National Kidney Foundation·Sarah Sanghavi, Joseph A Vassalotti
Sep 13, 2013·Annals of Internal Medicine·Csaba P KovesdyKamyar Kalantar-Zadeh
Oct 23, 2013·Annals of Internal Medicine·Amir QaseemUNKNOWN Clinical Guidelines Committee of the American College of Physicians
Nov 12, 2013·The New England Journal of Medicine·Linda F FriedUNKNOWN VA NEPHRON-D Investigators
Nov 26, 2013·Journal of the American College of Cardiology·Kevin Damman, Hiddo J Lambers-Heerspink
Sep 2, 2015·JAMA : the Journal of the American Medical Association·George L BakrisUNKNOWN Mineralocorticoid Receptor Antagonist Tolerability Study–Diabetic Nephropathy (ARTS-DN) Study Group
Sep 18, 2015·The New England Journal of Medicine·Bernard ZinmanUNKNOWN EMPA-REG OUTCOME Investigators
Sep 22, 2015·Expert Opinion on Pharmacotherapy·Diego F MárquezJulián Segura
Nov 5, 2015·Lancet·Patrick RossignolUNKNOWN Cardiovascular and Renal Clinical Trialists (F-CRIN INI-CRCT) network
Nov 10, 2015·The New England Journal of Medicine·UNKNOWN SPRINT Research GroupWalter T Ambrosius
Apr 8, 2016·Nature Reviews. Cardiology·Gema Ruiz-HurtadoLuis M Ruilope
May 25, 2016·JAMA : the Journal of the American Medical Association·Neil R Powe, Kirsten Bibbins-Domingo
May 25, 2016·JAMA : the Journal of the American Medical Association·Katherine T MillsUNKNOWN Chronic Renal Insufficiency Cohort (CRIC) Study Investigators
Jun 14, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN LEADER Trial Investigators
Jun 15, 2016·The New England Journal of Medicine·Christoph WannerUNKNOWN EMPA-REG OUTCOME Investigators
Aug 16, 2016·Journal of the American Society of Nephrology : JASN·Elaine KuChi-Yuan Hsu
Sep 17, 2016·The New England Journal of Medicine·Steven P MarsoUNKNOWN SUSTAIN-6 Investigators
Oct 8, 2016·Journal of the American College of Cardiology·Nancy R CookPaul K Whelton

❮ Previous
Next ❯

Citations

Oct 5, 2019·F1000Research·Diego Francisco MárquezLuis Ruilope

❮ Previous
Next ❯

Clinical Trials Mentioned

NCT02540993
NCT02545049

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.